This meta-analysis aims to provide insight on the efficacy of using combined biomarkers, AFP, AFP-L3, DCP, DKK-1, and GP73, for clinical decision-making for patients with HCC.
Fang YS, Wu Q, Zhao HC, Zhou Y, Ye L, Liu SS, Li XX, Du WD…
You are about to leave the Clinical Value website now.
The purpose of this study is to evaluate the prognostic values of serum markers in HCC, with retrospective data.
Li B, Liu A, Wen Y, Yang G, Zhao J, Li X, Mao Y, Li B…
This study aims to investigate the diagnostic role of PIVKA-II alone or in combination with AFP in Chinese HCC patients.
Xu F, Zhang L, He W, Song D, Ji X, Shao J…
The aim of this study was to investigate the efficacy of combined detection of 5 serological tumor markers including macrophage migration inhibitory factor (MIF) and abnormal prothrombin (PIVKA-II) in the early diagnosis of primary liver cancer.
Huan L…
Catch up on the highlights of APASL 2023 with this congress report, covering session on hepatitis B, hepatitis C, hepatocellular carcinoma, and fatty liver disease. …